Anti-Tumor and Anti-Microbial Inhibitors
- Detailed Technology Description
- None
- *Abstract
-
McGill University is seeking to outlicense novel compounds characterized as human FarnesylPyrophosphate Synthase (hFPPS) inhibitors. Human FPPS is responsible for the biosynthesis of farnesylpyrophosphate (FPP), the first branching point of the mevalonate metabolic pathway. FPPS also controlsintracellular levels of numerous down-stream isoprenoid and steroidal metabolites, including geranylgeranylpyrophosphate (GGPP), squalene and cholesterol. Both FPP and GGPP are essential for the posttranslational modification (prenylation) of small GTPases, a large family of signalling proteins that are importantfor cell survival. Intervention of this pathway is an approach that has found widespread clinical utility including:statins that inhibit hydroxymethylglutaryl-CoA reductase and cholesterol biosynthesis, and nitrogen-containing bisphosphonates (N-BPs) indicated for osteoporosis and bone cancer metastasis
- Country/Region
- USA
